Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis
Fadi Haddad(Trinity Health), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Sangeetha Venugopal(University of Miami), Tareq Abuasab(The University of Texas MD Anderson Cancer Center), Courtney DiNardo(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Rodrick Babakhanlou(The University of Texas MD Anderson Cancer Center), Sai Prasad Desikan(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Alexandre Bazinet(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Grace S. Park(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Hussein A. Abbas(The University of Texas MD Anderson Cancer Center), Jayastu Senapati(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Daniel Rivera(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Faustine Ong(The University of Texas MD Anderson Cancer Center)
Cited by 11
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k